Keros Therapeutics (NASDAQ:KROS) Lowered to "Market Perform" Rating by William Blair

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was downgraded by stock analysts at William Blair from an "outperform" rating to a "market perform" rating in a research report issued on Thursday, MarketBeat reports.

Several other equities analysts also recently commented on KROS. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wells Fargo & Company lifted their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They set a "buy" rating on the stock. Finally, Wedbush reaffirmed an "outperform" rating and issued a $84.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $95.22.

Keros Therapeutics Stock Down 73.2 %

Shares of Keros Therapeutics stock traded down $50.22 during trading on Thursday, reaching $18.43. The company's stock had a trading volume of 14,631,993 shares, compared to its average volume of 437,409. Keros Therapeutics has a 52-week low of $15.67 and a 52-week high of $73.00. The firm's 50-day moving average is $60.78 and its two-hundred day moving average is $53.07. The company has a market cap of $746.54 million, a price-to-earnings ratio of -3.08 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm's revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period last year, the firm posted ($1.33) EPS. On average, equities research analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV raised its stake in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics in the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics during the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at about $213,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.